Among them, ITRI-E-(S)4046 (MW = 379.3), which is a compound characterized by its dual kinase inhibition capabilities, stands out as a novel and highly specific inhibitor of both ROCK1/2 and MYLK4 (100% for ROCK1/2 and 99.5% for MYLK), that reduces IOP in ocular hypertension (OHT) animals with low incidence of ocular hyperemia.16 This evidence concerns the gene MYLK and ocular hypertension.